# A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT04614298** · PHASE4 · WITHDRAWN · sponsor: **Kyowa Kirin Co., Ltd.**

## Conditions studied

- Moderate to Severe Plaque Psoriasis

## Interventions

- **DRUG:** KHK4827-Active
- **DRUG:** KHK4827-Placebo

## Key facts

- **NCT ID:** NCT04614298
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01
- **Primary completion:** 2022-02
- **Final completion:** 2022-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to the reconsideration of KHK4827's business in China, it. was decided to withdraw this clinical trial prior to enrollment of first participant.
- **Last updated:** 2021-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04614298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04614298, "A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04614298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*